{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:42:28Z","timestamp":1794663748855,"version":"4.9.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"4","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Assessment of measurable residual disease (MRD) by quantitative reverse transcription polymerase chain reaction is strongly prognostic in patients with NPM1-mutated acute myeloid leukemia (AML) treated with intensive chemotherapy; however, there are no data regarding its utility in venetoclax-based nonintensive therapy, despite high efficacy in this genotype. We analyzed the prognostic impact of NPM1 MRD in an international real-world cohort of 76 previously untreated patients with NPM1-mutated AML who achieved complete remission (CR)\/CR with incomplete hematological recovery following treatment with venetoclax and hypomethylating agents (HMAs) or low-dose cytarabine (LDAC). A total of 44 patients (58%) achieved bone marrow (BM) MRD negativity, and a further 14 (18%) achieved a reduction of \u22654 log10 from baseline as their best response, with no difference between HMAs and LDAC. The cumulative rates of BM MRD negativity by the end of cycles 2, 4, and 6 were 25%, 47%, and 50%, respectively. Patients achieving BM MRD negativity by the end of cycle 4 had 2-year overall of 84% compared with 46% if MRD was positive. On multivariable analyses, MRD negativity was the strongest prognostic factor. A total of 22 patients electively stopped therapy in BM MRD-negative remission after a median of 8 cycles, with 2-year treatment-free remission of 88%. In patients with NPM1-mutated AML attaining remission with venetoclax combination therapies, NPM1 MRD provides valuable prognostic information.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023021579","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T21:45:09Z","timestamp":1693431909000},"page":"336-341","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":87,"title":["Molecular MRD is strongly prognostic in patients with <i>NPM1<\/i>-mutated AML receiving venetoclax-based nonintensive therapy"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-3576","authenticated-orcid":false,"given":"Jad","family":"Othman","sequence":"first","affiliation":[{"name":"1Department of Medical and Molecular Genetics, King's College London, London, United Kingdom"},{"name":"2Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom"},{"name":"3Faculty of Medicine and Health, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7417-4343","authenticated-orcid":false,"given":"Ing S.","family":"Tiong","sequence":"additional","affiliation":[{"name":"4Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"5Alfred Hospital and Monash University, Melbourne, Australia"},{"name":"6Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"O'Nions","sequence":"additional","affiliation":[{"name":"7Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Dennis","sequence":"additional","affiliation":[{"name":"8The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Mokretar","sequence":"additional","affiliation":[{"name":"9Cancer Genetics, Synnovis, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ivey","sequence":"additional","affiliation":[{"name":"5Alfred Hospital and Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4218-0284","authenticated-orcid":false,"given":"Michael","family":"Austin","sequence":"additional","affiliation":[{"name":"10Barts Cancer Institute, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Louise","family":"Latif","sequence":"additional","affiliation":[{"name":"11Department of Haematology, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Amer","sequence":"additional","affiliation":[{"name":"12Haematology, University Hospital Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0471-2059","authenticated-orcid":false,"given":"Wei Yee","family":"Chan","sequence":"additional","affiliation":[{"name":"7Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Crawley","sequence":"additional","affiliation":[{"name":"13Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Crolla","sequence":"additional","affiliation":[{"name":"14Haematology, Musgrove Park Hospital, Taunton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-7098","authenticated-orcid":false,"given":"Joe","family":"Cross","sequence":"additional","affiliation":[{"name":"15Haematology Department, University Hospital Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Dang","sequence":"additional","affiliation":[{"name":"16James Cook University Hospital, Middlesbrough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathon","family":"Elliot","sequence":"additional","affiliation":[{"name":"8The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Y.","family":"Fong","sequence":"additional","affiliation":[{"name":"6Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Galli","sequence":"additional","affiliation":[{"name":"17Frimley Park Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gallipoli","sequence":"additional","affiliation":[{"name":"10Barts Cancer Institute, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Hogan","sequence":"additional","affiliation":[{"name":"18University Hospital of Wales, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Kalkur","sequence":"additional","affiliation":[{"name":"19Southend Hospital, Southend, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6432-6999","authenticated-orcid":false,"given":"Anjum","family":"Khan","sequence":"additional","affiliation":[{"name":"20Department of Haematology, Leeds Teaching Hospitals Trust, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramila","family":"Krishnamurthy","sequence":"additional","affiliation":[{"name":"21Department of Haematology, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Laurie","sequence":"additional","affiliation":[{"name":"22Worthing Hospital, Worthing, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6294-2691","authenticated-orcid":false,"given":"Sun","family":"Loo","sequence":"additional","affiliation":[{"name":"4Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8574-7012","authenticated-orcid":false,"given":"Scott","family":"Marshall","sequence":"additional","affiliation":[{"name":"23City Hospitals Sunderland NHS Trust, Sunderland, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8561-1705","authenticated-orcid":false,"given":"Priyanka","family":"Mehta","sequence":"additional","affiliation":[{"name":"15Haematology Department, University Hospital Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhya","family":"Murthy","sequence":"additional","affiliation":[{"name":"24Centre for Clinical Haematology, University Hospitals Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4204-5317","authenticated-orcid":false,"given":"Sateesh","family":"Nagumantry","sequence":"additional","affiliation":[{"name":"25Peterborough City Hospital, Peterborough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Pillai","sequence":"additional","affiliation":[{"name":"26Royal Stoke University Hospital, University Hospital of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8256-9350","authenticated-orcid":false,"given":"Nicola","family":"Potter","sequence":"additional","affiliation":[{"name":"1Department of Medical and Molecular Genetics, King's College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Sellar","sequence":"additional","affiliation":[{"name":"7Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-8974","authenticated-orcid":false,"given":"Tom","family":"Taylor","sequence":"additional","affiliation":[{"name":"27Nottingham University Hospital, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-1672","authenticated-orcid":false,"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[{"name":"28Torbay Hospital, Torquay, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel H.","family":"Russell","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"4Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-5296","authenticated-orcid":false,"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[{"name":"1Department of Medical and Molecular Genetics, King's College London, London, United Kingdom"},{"name":"2Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2024012516213755100_bib1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024012516213755100_bib2","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","article-title":"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)","volume":"107","author":"Thiede","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2024012516213755100_bib3","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2014.58.0571","article-title":"Prognostic significance of NPM1 mutations in the absence of FLT3\u2013internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute\/Medical Research Council Report","volume":"33","author":"Ostronoff","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"2024012516213755100_bib4","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1200\/JCO.19.00416","article-title":"Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia:\u00a0a pooled analysis of individual patient data from nine international cohorts","volume":"37","author":"Angenendt","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2024012516213755100_bib5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2024012516213755100_bib6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2024012516213755100_bib7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2024012516213755100_bib8","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2024012516213755100_bib9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024012516213755100_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group","volume":"35","author":"Balsat","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2024012516213755100_bib11","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group","volume":"29","author":"Kr\u00f6nke","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024012516213755100_bib12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"2024012516213755100_bib13","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","article-title":"Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia","volume":"5","author":"Maiti","year":"2021","journal-title":"Blood Adv"},{"issue":"15","key":"2024012516213755100_bib14","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.3390\/cancers14153576","article-title":"Real-world experience of measurable residual disease response and prognosis in acute myeloid leukemia treated with venetoclax and azacitidine","volume":"14","author":"Ong","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"2024012516213755100_bib15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2024012516213755100_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2307\/2532740","article-title":"Maximally selected rank statistics","volume":"48","author":"Lausen","year":"1992","journal-title":"Biometrics"},{"issue":"14","key":"2024012516213755100_bib17","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1182\/bloodadvances.2022009379","article-title":"Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study","volume":"7","author":"Scott","year":"2023","journal-title":"Blood Adv"},{"issue":"13","key":"2024012516213755100_bib18","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv"},{"issue":"23","key":"2024012516213755100_bib19","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1182\/bloodadvances.2021005455","article-title":"Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia","volume":"5","author":"Tiong","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"2024012516213755100_bib20","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.2019002959","article-title":"Molecular MRD status and outcome after transplantation in NPM1-mutated AML","volume":"135","author":"Dillon","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2024012516213755100_bib21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"26","key":"2024012516213755100_bib22","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024012516213755100_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2022-158518","article-title":"Long-term follow-up of the phase 3 Viale-a clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy [abstract]","volume":"140","author":"Pratz","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2024012516213755100_bib24","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2024012516213755100_bib25","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1182\/blood-2022-163041","article-title":"A\u00a0prospective phase 2 study of venetoclax and low dose Ara-C (VALDAC) to target rising molecular measurable residual disease and early relapse in acute myeloid leukemia [abstract]","volume":"140","author":"Tiong","year":"2022","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2023021579\/2210307\/blood_bld-2023-021579-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2023021579\/2210307\/blood_bld-2023-021579-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T16:22:49Z","timestamp":1706199769000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/4\/336\/497721\/Molecular-MRD-is-strongly-prognostic-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,1,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021579","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]}}}